Relay Therapeutics opened lower at $19.46, compared with its previous close of $19.72. In the last trading session, the stock traded between $18.08 and $19.51. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Relay Therapeutics is now worth
$ 50.66
Resulting in a loss of
$ 49.34 (49.34%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 7 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-1.63 (-8.29%)
Day High
$19.51
Day Low
$18.08
Day Open
$19.46
Prev Close
$19.72
Volume
22,79,922
1W Return
0.33%
1M Return
0.53%
3M Return
-9.54%
6M Return
40.75%
1Y Return
187.54%
Fundamentals
Market Cap ($ Mn)
3,996
PE Ratio
-
PB Ratio
4.61
PEG Ratio
-
ROE
-41.40%
ROCE
-43.21%
EPS (TTM)
$-0.37
Investment Returns
1 Week
0.33%
1 Month
0.53%
3 Months
-9.54%
6 Months
40.75%
9 Months
97.66%
Financials
Quarterly
All values in $ Mn
7.7
Mar 25
0.7
Jun 25
0.0
Sep 25
7.0
Dec 25
0.3
Jun 26
0.0
Sep 26
Updates
2Sep
Relay Therapeutics to speak at Wells Fargo, Morgan Stanley conferences
Relay Therapeutics management to speak at two September 2026 conferences. Sessions scheduled for Sept 8 at Wells Fargo and Sept 16 at Morgan Stanley. Live webcasts and 30-day archived replays available via company website. Lead asset zovegalisib remains in Phase 3 trial for breast cancer.
2mo ago
7Aug
Relay Therapeutics Q2 Results: Sales drop 48% YoY, miss estimates
Relay Therapeutics missed Q2 analyst estimates with EPS of $(0.41) vs $(0.39) expected. Sales fell 48.30% YoY to $350.000K, missing the $872.727K estimate by 59.90%. The results reflect significant top-line pressure.
3mo ago
31Jul
Relay Therapeutics to report Q2 2026 results on Aug 6
Relay Therapeutics, Inc. will announce Q2 2026 results on August 6, 2026. The clinical-stage firm develops precision medicines, including Phase 3 asset zovegalisib for breast cancer and genetic diseases. Investors await updates on financial health and pipeline progress.
3mo ago
16Jul
Canaccord Genuity initiates coverage on Relay Therapeutics with Buy rating
Canaccord Genuity analyst John Newman has initiated coverage on Relay Therapeutics with a Buy rating and a price target of $29.
3mo ago
8Jul
JP Morgan initiates coverage on Relay Therapeutics with Overweight rating
JP Morgan analyst Priyanka Grover initiated coverage on Relay Therapeutics with an Overweight rating and a price target of $28, signaling a positive outlook for the stock.
